Related Experiment Video

Updated: Aug 6, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate

X Li1, S Sambhara, C X Li

  • 1Research Center, Pasteur Mérieux Connaught Canada, 1755 Steeles Avenue West, North York, Ontario, M2R 3T4, Canada.

Virology
|March 22, 2000
PubMed

Insights

New DNA-G vaccines show promise for preventing respiratory syncytial virus (RSV) by eliciting balanced immune responses without causing harmful lung inflammation in animal models, unlike older vaccine approaches.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Respiratory syncytial virus (RSV) is a significant cause of severe respiratory illness in vulnerable populations.
  • Past RSV vaccine development faced setbacks, notably enhanced lung disease in infants from formalin-inactivated vaccines.
  • Previous research linked enhanced lung pathology to Th2 immune responses against the RSV G protein.

Purpose of the Study:

  • To evaluate DNA-G vaccination for its ability to induce balanced immune responses against RSV.
  • To assess the safety and efficacy of DNA-G immunization in preventing RSV-induced lung disease.

Main Methods:

  • Vaccination of mice and cotton rats with plasmid vectors encoding full-length or secreted G protein (DNA-G).
  • Assessment of systemic and pulmonary cytokine responses (Th1/Th2 balance).
  • Evaluation of pulmonary inflammatory reactions post-RSV challenge.
  • Measurement of virus-neutralizing antibody titers and protection against lower respiratory tract infection.

Main Results:

  • DNA-G vaccination induced balanced Th1/Th2 cytokine responses in mice.
  • No atypical pulmonary inflammation was observed in cotton rats after RSV challenge.
  • Significant virus-neutralizing antibody responses were generated.
  • Effective protection against RSV lower respiratory tract infection in both species.

Conclusions:

  • DNA-G immunization elicits a balanced immune response, similar to live RSV infection.
  • DNA-G is a safe and effective immunogen, demonstrating potential for a nucleic acid-based RSV vaccine.
  • This approach overcomes previous safety concerns associated with RSV vaccine development.

More Related Videos

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus09:08

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

A Seamless Cloning Approach for Porcine Reproductive and Respiratory Syndrome Virus Expression Vector Construction04:18

A Seamless Cloning Approach for Porcine Reproductive and Respiratory Syndrome Virus Expression Vector Construction

Published on: May 17, 2024

Related Concept Videos

Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Coronavirus01:29

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...